Поиск
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.

Список литературы

  1. Brown M.L., Dearani J.A., Danielson G.K. et al. The outcomes of operations for 539 patients with Ebstein anomaly. J Thorac Cardiovasc Surg 2008; 135:1120–36.
  2. Бокерия Л.А., Шаталов К.В. (ред.). Детская кардиохирургия. Руководство для врачей. ФГБУ "НМИЦССХ им. А.Н. Бакулева" МЗ РФ, 2016, с. 294-312.
  3. Giamberti A., Chessa M. The Tricuspid Valve in Congenital Heart Disease Springer-Verlag Italia 2014
  4. Бокерия Л.А., Подзолков В.П., Сабиров Б.Н. в кн. Аномалия Эбштейна // М.2005, 151-206.
  5. Walsh E.P. Ebsteins anomaly of the tricuspid valve. A natural laboratory for re-entrant tachycardias.   J. am. Coll. Cardiol. EP. 2018, 4, 1271-1288.
  6. Janson CM, Shah MJ Supraventricular Tachycardia in Adult Congenital Heart Disease Mechanisms, Diagnosis, and Clinical Aspects. Card Electrophysiol Clin 9 (2017) 189–211.
  7. Khairy P. Arrhythmias in Adults With Congenital Heart Disease: What the Practicing Cardiologist Needs to Know. Canadian Journal of Cardiology 35 (2019) 1698-1707.
  8. Mavroudis C., Dearani J.A.  Atlas of Adult Congenital Heart Surgery    Springer Nature Switzerland AG 2020
  9. Roten L, Lukac P, DeGrootNetal. Catheter ablation of arrhythmias in Ebstein’sanomaly: amulticenterstudy. J Cardiovasc Electrophysiol 2011;22:1391-1396.
  10. Wackel Ph., Cannon B., Dearani J., Session K., Holst K., Johnson J., Cetta F.  Arrhythmia after cone repair for Ebstein anomaly: the Mayo clinic experience in 143 young patients.  Congenit Heart Dis.  2018. Jan;13(1):26-30.
  11. Delhaas T., du Marchie Sarvaas G., Rijlaarsdam M., Strengers J., Eveleigh R., Poulino S., de Korte Ch., Kapusta L.  A multicenter, long-term study on arrhythmias in children with Ebstein  anomaly. Pediatr Cardiol, 2010. 31, 229-233.
  12. Raju V, Dearani JA, Burkhart HM, et al. Right ventricular unloading for heart failure related to Ebstein’s malformation. Ann Thorac Surg. 2014 Jul;98(1):167-73; discussion 173-4.
  13. Obioha-Ngwu O, Milliez P, Richardson A et al. Ventricular tachycardia in Ebstein’s anomaly. Ci Circulation 2001 Oct 30;104(18):E92-4.
  14. Shivapour JKL, Sherwin ED, Alexander ME, et al. Utility of preoperative electrophysiologic studies in patients with Ebstein’s anomaly undergoing the Cone procedure. Heart Rhythm 2014;11:182-186.
  15. KubusP, VıtP, GebauerRA, MaternaO, JanousekJ. Electro physiologic profile and results of invasive risk stratificationin a symptomatic children and adolescents with the Wolff-Parkinson-White electrocardiographic pattern.Circ Arrhythm Electrophysiol 2014;7:218-223.
  16. McIntosh, N., Chitayat, D., Bardanis, M., Fouron, J.-C. Ebstein anomaly: report of a familial occurrence and prenatal diagnosis. Am. J. Med. Genet. 42: 307-309, 1992. 
  17. deLonlay-Debeney, P., deBlois, M.-C., Bonnet, D., Amiel, J., Abadie, V., Picq, M., Lyonnet, S., Sidi, D., Munnich, A., Vekemans, M., Cormier-Daire, V. Ebstein anomaly associated with rearrange ments of chromosome alregion 11q. Am. J. Med. Genet. 80: 157-159, 1998.
  18. Digilio, M. C., Bernardini, L., Lepri, F., Giuffrida, M. G., Guida, V., Baban, A., Versacci, P., Capolino, R., Torres, B., DeLuca, A., Novelli, A., Marino, B., Dallapiccola, B. Ebstein anomaly: genetic heterogeneity and association with microdeletions 1p36 and 8p23.1. Am. J. Med. Genet. 155A: 2196-2202, 2011.
  19. Harvey RP. NK-2 homeobox genes and heart development. Developmental Biology. 1996;178(2):203–216. doi: https://doi.org/10.1006/dbio.1996.0212
  20. Postma AV, van Engelen K, van de Meerakker J, et al. Mutations in the sarcomere gene MYH7 in Ebstein anomaly. Circ Cardiovasc Genet. 2011;4(1):43–50. doi: https://doi.org/10.1161/CIRCGENETICS.110.957985
  21. Пеняева Е.В. . Генетические аспекты аномалии Эбштйна и связанных с ней заболеваний сердца //Вестник РАМН. — 2021. — Т. 76. — № 1. — С. 67–74.
  22. Celemajer D.S., CullenS., SullivanI.D., etal. Outcome in neonates with Ebstein"s anomaly // J. Am. Coll. Cardlol. - 1992. -Vol. 19, N 5. - P.1041-1046.
  23. Бураковский В.И., Бокерия Л.А. Сердечно-сосудистая хирургия // Руководство.-1989. С. 471-512.
  24. Lang D, Oberhoffer R., Cook A. et al. Pathologic spectrum of malformations of the tricuspid valve in prenatal  and  neonatal life // J. Am. Coil. Cardlol. - 1991. - Vol.17. - P.1161-1167.
  25. Sharland G.K..  Chita  S.K..  Allan  L.D.  Tricuspid  valve dysplasia  or  displacement  in  mtrauterlne life // J. Am. Coil. Cardlol. - 1991. - Vol. 17. - P.944-949.
  26. Castaneda A.R., Jonas R.A., Mayer J.E., Hanley F.L. Ebstein"s anomaly //Books: Cardiac Surgery of the Neonate and Infant .1994.-P.273-280
  27. Carpentier A., Chauvaud S.,Mace L. et al. A new reconstructive operation for Epstein’s anomaly of the tricuspid valve // J.Thorac.Cardlovase.Surg. - 1988.- Vol.96, N1.- P.92-101.
  28. Sano S., Fujii Y., Kasahara S., Kuroko Y., Tateishi A., Yoshizumi k., Arai S.  Repair of Ebsteins anomaly in neonates and small infants: impact of right ventricular exclusion and its indications. European Journal of Cardio-Thoracic Surgery, Volume 45, Issue 3, March 2014, Pages 549–555,
  29. Mizuno M., Hoashi T., Sakaguchi H., Kagisaki K., Kitano M., Kurosaki K., Yoshmaysu J., Shiraishi I., Ichikawa H.  Applacation of cone reconstruction for neonatal Ebstein anomaly or tricuspid valve dysplasia.   Ann. Thorac. Surgery. 2016. 101. 1811-1817.
  30. Stout K.K. et al. 2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.J Am Coll Cardiol. 2019 Apr 2;73(12):e81-e192. 
  31. Baumgartner H, De Backer J, Babu-Narayan SV et al. 2020 ESC Guidelines for the management of adult congenital heart disease.Eur Heart J. 2021 Feb 11;42(6):563-645.
  32. Бокерия Л. А., Бокерия О. Л., Сабиров Б. Н. и др. Современный подход и результаты одномоментной коррекции аномалии Эбштейна и синдрома Вольфа–Паркинсона–Уайта / // Грудная и сердечно-сосудистая хирургия. – 2012. – № 1. – С. 4-11.
  33. Caldeira D., David C., Costa J., Ferreira J.J., Pinto F.J. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2018;4:111-118.
  34. Бокерия Л.А., Голухова Е.З., Ревишвили А.Ш и др. Дифференцированный подход к хирургическому лечению аномалии Эбштейна, сочетающейся с синдромом Вольфа-Паркинсона-Уайта //Грудная и сердечно-сосудистая хирургия. -2003. - N 2, - С.12-17.
  35. Клиническая лабораторная диагностика: учебник / Под ред. В.В. Долгова, ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования». – М.: ФГБОУ ДПО РМАНПО, 2016. – 668 с.
  36. Brugada J., et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC).Eur Heart J. 2019.
  37. Rodseth RN, Biccard BM, Le Manach Y, Sessler DI, Lurati Buse GA, Thabane L et al. The prognostic value of pre-operative and post-operative B-type natriuretic peptides in patients undergoing noncardiac surgery: B-type natriuretic Peptide and N-terminal fragment of pro-B-type natriuretic Peptide: a systematic review and individual patient data meta-analysis. J Am Coll Cardiol 2014;63:170 –180.
  38. Lopes L. M. et al. The role of echocardiography as an isolated method for indicating surgery in patients with congenital heart disease //Arquivos Brasileiros de Cardiologia. – 2005. – Т. 84. – №. 5. – С. 381-386.
  39. Iturralde P. et al. Electrocardiographic characteristics of patients with Ebstein"s anomaly before and after ablation of an accessory atrioventricular pathway //Journal of cardiovascular electrophysiology. – 2006. – Т. 17. – №. 12. – С. 1332-1336.
  40. Danielson G.K., Fuster V.  Surgical repair of Epstein’s anomaly // Ann. Surg. - 1982. - Vol. 196, N 4. - P.499-504.
  41. Бокерия Л.А.  в кн. Тахиаритмии //М.1989, С.73-121
  42. DeWitt ES, Beausejour-Ladouceur V, Whitehill R, Radiofrequency ablation versus medical therapy for first episode of atrial tachycardia in adults with congenital heart disease. Heart Rhythm 2016;13:S449.
  43. Park JB, Lee SP, Lee JH et al. Quantification of right ventricular volume and function using single-beat three-dimensional echocardiography: a validation study with cardiac magnetic resonance. J Am Soc Echocardiogr 2016;29:392–401.
  44. Kumor M. et al. Cardiac arrest and ventricular arrhythmia in adults with Ebstein anomaly and left ventricular non-compaction //Journal of cardiology. – 2018. – Т. 71. – №. 5. – С. 484-487.
  45. Chauvaud S. M., Brancaccio G., Carpentier A. F. Cardiac arrhythmia in patients undergoing surgical repair of Ebstein’s anomaly //The Annals of thoracic surgery. – 2001. – Т. 71. – №. 5. – С. 1547-1552.
  46. Kirklin J.W., Barratt-Boyes B.G. Cardiac surgery: Morphology, diagnostic criteria, natural history, techniques, results, and indications. 4rd ed. N.Y.; 2013.
  47. Negoi, R. I., Ispas, A. T., Ghiorghiu, I., Filipoiu, F., Negoi, I., Hostiuc, M., … Ginghina, C. (2013). Complex Ebstein’s Malformation: Defining Preoperative Cardiac Anatomy and Function. Journal of Cardiac Surgery, 28(1), 70–81. doi:10.1111/jocs.12032
  48. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010;56:1527–1534.
  49. Rydman R., Shiina Y., Diller G.P., Niwa K., Li W., Uemura H., Uebing A., Barbero U., Bouzas B., Ernst S., Wong T., Pennell D.J., Gatzoulis M.A., Babu-Narayan S.V. Major adverse events and atrial tachycardia in Ebstein’s anomaly predicted by cardiovascular magnetic resonance. Heart 2018;104:37_44.
  50. Ahmed S. et al. Transesophageal three‐dimensional echocardiographic demonstration of Ebstein"s anomaly //Echocardiography. – 2003. – Т. 20. – №. 3. – С. 305-307.
  51. van Noord P. T. et al. Three-dimensional transesophageal echocardiography in Ebstein"s anomaly //Interactive cardiovascular and thoracic surgery. – 2010. – Т. 10. – №. 5. – С. 836-837.
  52. Филатов А.Г., Горячев В.А. Роль электрофизиологического исследования в выборе тактики лечения патологии аномалии Эбштейна в сочетании с дополнительным предсердно-желудочковым соединением // Анн.аритм.. 2018. №4.
  53. Iturralde P, Nava S, Sálica G, et al. Electro-cardiographic characteristics of patients with Ebstein’s anomaly before and after ablation of an accessory atrioventricular pathway. J Cardiovasc Electrophysiol. 2006;17:1332–6.
  54. Dongshan Zhu, Hsin-Fang Chung, Annette J Dobson et al. Age at natural menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. Lancet Public Health. 2019 Nov;4(11):e553-e564.
  55. Diller G.P., Dimopoulos K., Okonko D., Li W., Babu-Narayan S.V., Broberg C.S., Johansson B., Bouzas B., Mullen M.J., Poole-Wilson P.A., Francis D.P., Gatzoulis M.A. Exercise intolerance in adult congenital heart disease: comparative severity, cor- . relates, and prognostic implication. Circulation 2005;112:828-835.
  56. Sian Pincott E., Burch M. Indications for heart transplantation in congenital heart disease //Current cardiology reviews. – 2011. – Т. 7. – №. 2. – С. 51-58.
  57. Book WM, Shaddy RE.Medical therapy in adults with congenital heart disease. Heart Fail Clin. 2014 Jan;10(1):167-78.
  58. Диагностика и лечение ХСН у детей и подростков, методические рекомендации  Ассоциация детских кардиологов Москва 2010, 80С.
  59. Kantor PF., Lougheed J, Dancea A, McGillon M et al. Children"s Heart Failure Study Group. Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines. Canadian J.Cardiology 2013 Dec; 29 (12): 1535-1552
  60. Priori S.G., Blomström-Lundqvist C., Mazzanti A. et al. 2015 ЕSC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac Death. The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology. – Eur Heart J.–2015. –36(41).– p. 2793–867.
  61. Budts W., Borjesson M., Chessa M., vanBuuren F., Trigo Trindade P., Corrado D., Heidbuchel H., Webb G., Holm J., Papadakis M. Physical activity in adolescents and adults with congenital heart defects: individualized exercise prescription. Eur. Heart J 2013;34:3669-3674.
  62. Gheorghiade M., Patel K., Filippatos G. et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur J Heart Fail. 2013;15 (5):551–559
  63. Rathore S.S., Curtis J.P., Wang Y. et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289 (7):871–878.
  64. Bosnic Z. et al. Pathophysiological Complexity of Amiodarone-Induced Hypothyroidism (AIH) in patient With Congenital Heart Disease-Ebstein Anomaly: a case report. – 2021.
  65. Hernández-Madrid A, Paul T, Abrams D et al. Arrhythmias in congenital heart disease: a position paper of the European Heart Rhythm Association (EHRA), Association for European Paediatric and Congenital Cardiology (AEPC), and the European Society of Cardiology (ESC) Working Group on Grown-up Congenital heart disease, endorsed by HRS, PACES, APHRS, and SOLAECE.Europace. 2018 Nov 1;20(11):1719-1753.
  66. Beaufort-Krot G.C., Dijkstra S.S., Bink-Boelkens M.T. Natural history of ventricutar premature contractions in children with a structurally normal heart: does origin matter? Europace 2008; 10:998-1003
  67. Wang S., Zhu W., Hamilton R.M., Kirsh J.A., Stephenson E.A., Gross G.J. Diagnosis specific characteristics of ventricutar tachycardia in children with structurally normat hearts. Heart Rhythm 2010; 7:1725-1731.
  68. Collins K.K., Schaffer M.S., Liberman L., Saarel E., Knecht M., Tanet R.E., Bradley D., Dubin A.M., Paul T., Salerno J., Bar-Cohen Y., Sreeram N., Sanatani S., Law I.H., Btaufox A.,Batra A., Mottedo J.M., van Hare G.F., Reed J., Ro P.S., Kugter J., Anderson C., Triedman J.K. Fascicular and nonfascicular left ventricular tachycaralias in the young: an international multicenter study. J Cardiovasc Electrophysiol 2013; 2.4:640-648
  69. Pappone C, Vicedomini G, Manguso F, et al. Risk of malignant arrhythmias in initially symptomatic patients with Wolff-Parkinson-White syndrome: results of a prospective long-term electrophysiological follow-up study. Circulation 2012;125:661-668.
  70. Renda G, Ricci F, Giugliano RP, De Caterina R. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease. J AmColl Cardiol 2017;69:1363-1371.
  71. Roldan V, Marin F, Manzano-Fernandez S et al The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2013;62:2199–2204,390–392.
  72. Khairy P, Van Hare G, Balaji S, et al. 2014 Society guidelines: PACES/HRS expert consensus statement on the recognition and management of arrhythmias in adults congenital heart disease. Developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adults Congenital Heart Disease (ISACHD). Heart Rhythm 2014;11:e102–65
  73. Ahmed H., VanderPluym C. Medical management of pediatric heart failure //Cardiovascular Diagnosis and Therapy. – 2021. – Т. 11. – №. 1. – С. 323.
  74. Heidbuchel H., Verhamme P., Alings Metal. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonistanti coagulants in patients with non-valvular atrial fibrillation. Europace 2015;17:1467–1507.
  75. Giglia T. M. et al. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association //Circulation. – 2013. – Т. 128. – №. 24. – С. 2622-2703.
  76. Jensen AS, Idorn L, Norager B. et al. Anticoagulation in adults with congenital heart disease: the who, the when and the how? Heart 2015;101:424-429.
  77. Waldmann V, Laredo M, Abadir S, Mondésert B et al. Atrial fibrillation in adults with congenital heart disease. Int J Cardiol. 2019 Jul 15;287:148-154.
  78. Olesen JB, Lip GY, Hansen M.L et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.
  79. Di Russo G. B., Gaynor J. W. Ebstein"s anomaly: indications for repair and surgical technique //Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual. – WB Saunders, 1999. – Т. 2. – №. 1. – С. 35-50.
  80. Prakash S. et al. Bioprosthetic valve replacement in Ebstein’s anomaly //Indian Journal of Thoracic and Cardiovascular Surgery. – 2010. – Т. 26. – №. 3. – С. 179-184.
  81. Pujol C. et al. Usefulness of direct oral anticoagulants in adult congenital heart disease //The American journal of cardiology. – 2016. – Т. 117. – №. 3. – С. 450-455.
  82. Belli E. et al. Ebstein"s anomaly in adults: modified cone reconstruction of the tricuspid valve is associated with promising outcomes //Archives of cardiovascular diseases. – 2017. – Т. 110. – №. 5. – С. 325-333.
  83. Bradley S. M. et al. Anticoagulation in children with mechanical valve prostheses //The Annals of thoracic surgery. – 1997. – Т. 64. – №. 1. – С. 30-36.
  84. Holst K.A., Connolly H.M., Dearani J.A. Ebstein"s Anomaly. Methodist Debakey Cardiovasc J. 2019 Apr-Jun;15(2):138-144.
  85. van Slooten Y. Cardiovascular prostheses in congenital heart disease: дис. – University of Groningen, 2014.
  86. Boston U. S. et al. Tricuspid valve repair for Ebstein’s anomaly in young children: a 30-year experience //The Annals of thoracic surgery. – 2006. – Т. 81. – №. 2. – С. 690-696.
  87. Ross, F. J., Latham, G. J., Richards, M., Geiduschek, J., Thompson, D., & Joffe, D. (2015). Perioperative and Anesthetic Considerations in Ebstein’s Anomaly. Seminars in Cardiothoracic and Vascular Anesthesia, 20(1), 82–92. doi:10.1177/1089253215605390
  88. Sherwin ED, Abrams D.J. Ebstein Anomaly. Card Electrophysiol Clin 9 (2017) 245–254.
  89. da Silva J.P., Baumgratz J.F., da Fonseca L. et al. The cone reconstruction of the tricuspid valve in Ebstein’s anomaly. The operation: early and midterm results. J Thorac Cardiovasc Surg. 2007 Jan;133(1):215-23.
  90. Orczykowski M., Derejko P., Bodalski R., Urbanek P., Zakrzewska-Koperska J., Sierpiński R. et al. Radiofrequency catheter ablation of accessory pathways in patients with Ebstein"s anomaly: at 8 years of follow-up. Cardiol. J. 2017; 24 (1): 1–8. DOI: 10.5603/CJ.a2016.0111.
  91. Horstkotte D. et al. Benefits of endocarditis prevention in patients with prosthetic heart valves //Zeitschrift fur Kardiologie. – 1986. – Т. 75. – №. 1. – С. 8-11.
  92. Connolly H. M. et al. Management and prognosis of Ebstein anomaly. – 2019.
  93. Siripornpitak S. et al. CT and MRI for Repaired Complex Adult Congenital Heart Diseases/ Korean J Radiol . 2021 Mar;22(3):308-323.
  94. Qureshi MY, Dearani JA. Commentary: Gold or silver? Value of cardiac magnetic resonance imaging over echocardiography in Ebstein"s anomaly. J Thorac Cardiovasc Surg. 2021 Mar;161(3):1109-1110.
  95. Qureshi MY, O"Leary PW, Connolly HM. Cardiac imaging in Ebstein anomaly. Trends Cardiovasc Med. 2018 Aug;28(6):403-409. 
  96. Yang D, Li X, Sun JY, Cheng W, Greiser A, Zhang TJ, Liu H, Wan K, Luo Y, An Q, Chung YC, Han Y, Chen YC. Cardiovascular magnetic resonance evidence of myocardial fibrosis and its clinical significance in adolescent and adult patients with Ebstein"s anomaly. J Cardiovasc Magn Reson. 2018 Sep 27;20(1):69.
  97. Steinmetz M, Broder M, Hösch O, Lamata P, Kutty S, Kowallick JT, Staab W, Ritter CO, Hasenfuß G, Paul T, Lotz J, Schuster A. Atrio-ventricular deformation and heart failure in Ebstein"s Anomaly - A cardiovascular magnetic resonance study. Int J Cardiol. 2018 Apr 15;257:54-61.
  98. Baessato F, Furtmüller C, Shehu N, Ferrari I, Reich B, Nagdyman N, Martinoff S, Stern H, Ewert P, Meierhofer C. Detection of early signs of right ventricular systolic impairment in unoperated Ebstein"s anomaly by cardiac magnetic resonance feature tracking. Cardiovasc Diagn Ther. 2022 Jun;12(3):278-288. 
  99. Trivedi JK, Mahapatra RP, Gandham RK, Ramakrishna GV, Satapathy SK, Mohanty SK, Suresh A. Ebstein"s anomaly presenting with the acute coronary syndrome-a rare combination. Indian J Thorac Cardiovasc Surg. 2020 Jan;36(1):56-59.
  100. Attenhofer Jost CH, Connolly HM, O’Leary PW, Warnes CA, Tajik AJ, Seward JB. Left heart lesions in patients with Ebstein anomaly. Mayo Clin Proc.2005;80:361-8.
  101. Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines on the Management of Adults With Congenital Heart Disease). Developed in collaboration with the American Society of Echocardiography, Heart Rhythm Society, International Society for Adult Congenital Heart Disease, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 23: e143–263.
  102. Saxena A, Relan J, Agarwal R, Awasthy N, Azad S, Chakrabarty M. et all. Indian guidelines for indications and timing of intervention for common congenital heart diseases: Revised and updated consensus statement of the Working group on management of congenital heart diseases. Ann Pediatr Cardiol. 2019 Sep-Dec; 12(3):254-286.
  103. Schultz K, Haeffele CL. Heart failure in the adult Ebstein patient. Heart Fail Rev. 2020 Jul;25(4):623-632.
  104. Kimberly Holst NMA, Joseph AD. Diagnosis and management of adult congenital heart disease. III ed 46.
  105. Dinardo JA (2013) Heart failure associated with adult congenital heart disease. Semin Cardiothorac Vasc Anesth 17:44–54 47.
  106. Shaddy RE, Webb G (2008) Applying heart failure guidelines to adult congenital heart disease patients. Expert Rev Cardiovasc Ther 6:165–174.
  107. Fuchs MM, Connolly HM. Ebstein Anomaly in the Adult Patient. Cardiol Clin. 2020 Aug;38(3):353-363.
  108. Tam B, Chhay A, Yen L, Tesoriero L, Ramanathan R, Seri I, Friedlich PS (2014) Acetazolamide for the management of chronic metabolic alkalosis in neonates and infants. Am J Ther 21:477–481.
  109. Andrews MG, Johnson PN, Lammers EM, Harrison DL, Miller JL (2015) Acetazolamide in critically ill neonates and children with metabolic alkalosis. Ann Pharmacother 47:1130–1135. 
  110. Nikolaus A.Haas, Karl R.Schirmer/ Guidelines for the management of congenital heart diseases in childhood and adolescence/ doi:10.1017/S1047951116001955,Cambridge University press , 2017.S17-S19
  111. Klinge JM, Scharf J, Hofbeck M, Gerling S, Bonakdar S, Singer H. Intermittent administration of furosemide versus continuous infusion in the postoperative management of children following open heart surgery. Intensive Care Med. 1997 Jun;23(6):693-7.
  112. Jain S, Vaidyanathan B. Digoxin in management of heart failure in children: Should it be continued or relegated to the history books? Ann Pediatr Cardiol. 2009 Jul;2(2):149-52.
  113. Echt D S, LiebsonP R, MitchellL B, PetersR W, Obias-MannoD, BarkerA H, ArensbergD, BakerA, FriedmanL, GreeneH L. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med. 1991;324 (12):781–8.
  114. Saul J Philip, ScottWilliam A, BrownStephen, MarantzPablo, AcevedoValeria, EtheridgeSusan P, PerryJames C, TriedmanJohn K, BurrissSusan W, CargoPaul, GraepelJay, KoskeloEeva-Kaarina, WangRebecca. Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial. Circulation. 2005;112 (22):3470–7.
  115. Labombarda Fabien, OuPhalla, StosBertrand, de BlicJacques, VillainElisabeth, SidiDaniel. Acute amiodarone-induced pulmonary toxicity: an association of risk factors in a child operated by arterial switch operation. Congenit Heart Dis. 2008;3 (5):365–7.
  116. Haas Nikolaus A, CamphausenChristoph K. Impact of early and standardized treatment with amiodarone on therapeutic success and outcome in pediatric patients with postoperative tachyarrhythmia. J. Thorac. Cardiovasc. Surg. 2008;136 (5):1215–22.
  117. Thorne S A, BarnesI, CullinanP, SomervilleJ. Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease. Circulation. 1999;100 (2):149–54.
  118. Moe TG, Abrich VA, Rhee EK. Atrial Fibrillation in Patients with Congenital Heart Disease. J Atr Fibrillation. 2017 Jun 30;10(1):1612.
  119. Moore BM, Cordina RL, McGuire MA, Celermajer DS. Efficacy and adverse effects of sotalol in adults with congenital heart disease. Int J Cardiol. 2019 Jan 1;274:74-79.
  120. Malloy-Walton LE, Von Bergen NH, Balaji S, Fischbach PS, Garnreiter JM, Asaki SY, Moak JP, Ochoa LA, Chang PM, Nguyen HH, Patel AR, Kirk C, Sherman AK, Avari Silva JN, Saul JP. IV Sotalol Use in Pediatric and Congenital Heart Patients: A Multicenter Registry Study. J Am Heart Assoc. 2022 May 3;11(9):e024375.
  121. Colli A, Verhoye JP, Heijmen R, Strauch JT, Hyde JA, Pagano D, Antunes M, Koertke H, Ohri SK, Bail DH, Leprince P, Van Straten BH, Gherli T; ACTION Registry Investigators. Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results. Eur J Cardiothorac Surg. 2008 Apr;33(4):531-6.
  122. ElBardissi AW, DiBardino DJ, Chen FY, Yamashita MH, Cohn LH. Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm? J Thorac Cardiovasc Surg. 2010 May;139(5):1137-45.
  123. Nowell J, Wilton E, Markus H, Jahangiri M. Antithrombotic therapy following bioprosthetic aortic valve replacement. Eur J Cardiothorac Surg. 2007 Apr;31(4):578-85. 
  124. Bonow RO, Carabello BA, Kanu C, de Leon AC, Jr., Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O’Gara PT, O’Rourke RA, Otto CM, Shah PM, Shanewise JS, Smith SC, Jr., Jacobs AK, Adams CD, Anderson JL, Antman EM, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Hunt SA, Lytle BW, Nishimura R, Page RL, Riegel B. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006;114:e84—231.
  125. Купряшов А.А., Токмакова К.А. Нарушения системы свёртывания крови в сердечно-сосудистой хирургии. В кн.: Система гемостаза. Теоретические основы и клиническая практика: Национальное руководство / О.А. Рукавицын, С.В. Игнатьев, А.Г. Румянцев [и др.]. Москва: Общество с ограниченной ответственностью Издательская группа "ГЭОТАР-Медиа", 2024. 944 с. ISBN 978-5-9704-8497-5.
  126. Boucher AA, Heneghan JA, Jang S, Spillane KA, Abarbanell AM, Steiner ME, Meyer AD. A Narrative review of postoperative anticoagulation therapy for congenital cardiac disease. Front Surg. 2022 Jun 14;9:907782. doi: 10.3389/fsurg.2022.907782. PMID: 35774388; PMCID: PMC9237365.
  127. Monagle P, Chan AKC, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Göttl U, Vesely SK. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e737S-e801S.
  128. Separham A, Ghaffari S, Aslanabadi N, Sohrabi B, Ghojazadeh M, Anamzadeh E, Hajizadeh R, Davarmoin G. Prosthetic valve thrombosis. J Card Surg. 2015 Mar;30(3):246-50. 
  129. Van Nooten GJ, Caes F, Taeymans Y, Van Belleghem Y, François K, De Bacquer D, Deuvaert FE, Wellens F, Primo G. Tricuspid valve replacement: postoperative and long-term results. J Thorac Cardiovasc Surg 1995;110:672-9.
  130. Thorburn CW, Morgan JJ, Shanahan MX, Chang VP. Long-term results of tricuspid valve replacement and the problem of prosthetic valve thrombosis. Am J Cardiol 1983;51:1128-32.
  131. Yaminisharif A, Alemzadeh-Ansari MJ, Ahmadi SH. Prosthetic tricuspid valve thrombosis: three case reports and literature review. J Tehran Heart Cent 2012;7:147-55.
  132. Shin HS, Kim KH, Lee HS, Choi HM, Lee SA, Park EA, Kim HK. Organized prosthetic tricuspid valve thrombosis treated successfully with medical treatment. J Cardiovasc Ultrasound. 2013 Dec;21(4):192-6.
  133. Подзолков В.П., Кассирский Г.И. (ред.). Реабилитация больных после хирургического лечения врожденных пороков сердца. М.: НЦССХ им. А.Н. Бакулева; 2015.
  134. Подзолков В.П., Алекян Б.Г., Кокшенев И.В., Чебан В.Н. Повторные операции после коррекции врожденных  пороков  сердца. М.: НЦССХ  им. А.Н. Бакулева РАМН; 2013.
  135. Демин А.А., Кобалава Ж.Д., Скопин И.И. и др. Инфекционный эндокардит и инфекция внутрисердечных устройств. Клинические рекомендации 2021. Российский кардиологический журнал. 2022;27(10):5233.doi:10.15829/1560-4071-2022-5233.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу